Iatrogenic hyperkalemia as a serious problem in therapy of cardiovascular diseases in elderly patients

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 3, 2009, Pages 141-147

  Wozakowska Kapłon, Beata ^a,b   Janowska Molenda, Iwona ^a  

^a Swietokrzyski Center of Cardiology Kielce   (Poland)

^b Swietokrzyskie Centrum Kardiologii Poland   (Poland)

Author keywords

Cardiovascular diseases; Elderly patients; Iatrogenic hyperkalemia

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMILORIDE; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GLUCONATE CALCIUM; INSULIN; ION EXCHANGE RESIN; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; POLYSTYRENESULFONATE SODIUM; POTASSIUM; POTASSIUM CHLORIDE; SALBUTAMOL; SPIRONOLACTONE; THIAMAZOLE;

ADULT; AGED; ARTICLE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPLETE HEART BLOCK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; ELDERLY CARE; ELECTROLYTE BLOOD LEVEL; FEMALE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART PACING; HEMODIALYSIS; HOSPITAL ADMISSION; HUMAN; HYPERKALEMIA; HYPERTENSION; IATROGENIC DISEASE; IATROGENIC HYPERKALEMIA; INCIDENCE; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MALE; MONOTHERAPY; POLYPHARMACY; POTASSIUM BLOOD LEVEL; POTASSIUM INTAKE; TOXIC GOITER; TREATMENT OUTCOME;

EID: 64149098797     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.632     Document Type: Article

References (18)

1. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351:543-551.
2. Kokot F. [Water-electrolyte and acid-base balance in physiological state]. Warszawa, PZWL, 2005. Polish.
3. Giebisch G. Renal potassium channels: function, regulation and structure. Kidney Int. 2001; 60: 436-445.
4. Zaremba M, Franek E, Rydzewski A. [Hyperkalemia]. Chor Ser Nacz. 2006; 3: 36-40. Polish
5. Da̧browska B, Da̧browski A. [Handbook of electrocardiography] . Warszawa, PZWL, 2000: 326-327. Polish.
6. Dickstein K, Cohen-Solal A, Filippatos E, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008; 29: 2388-2442.
7. Messerli FH, Mancia G, Conti CR, et al. Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of ESC. Eur Heart J. 2006; 27: 2902- 2973.
8. Van de Werf F, Betriu A, Cokkinos DV, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of ESC. Eur Heart J. 2003; 24: 28-66.
9. Mancia M, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European Society of Cardiology. J Hypertens. 2007; 25:1105-1187.
10. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension of patient 80 years of age or older. N Engl J Med. 2008; 358:1887-1898.
11. McMurray JJ. Effect of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting- enzyme inhibitors: the CHARM-Altemative trial. Lancet. 2003; 362:767-771.
12. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709- 717.
13. Pitt B, Remme WJ, Zannad F, et al. Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348:1309-1321.
14. Flesch M, Erdmann E. The problem of polypharmacy in heart failure. Curr Cardiol Rep. 2006; 8:217-225.
15. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-551.
16. Kokot F, Hyla-Klekot L. Drug-induced abnormalities of potassium metabolism. Pol Arch Med Wew. 2008; 118: 431-433.
17. The 0NTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for cardiovascular events. N Engl J Med. 2008; 358: 1547-1559.
18. Cockroft D, Gault MK. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-36.